Abbott Laboratories (NYSE:ABT) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. On January ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Abbott Laboratories ended the fourth quarter with sales growth below Wall Street’s expectations, driven primarily by ongoing ...

Abbott's Medical Devices segment, especially CGM, continues to deliver robust double-digit growth, offsetting Nutrition ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Abbott Labs stock drops on sales miss and weak guidance for 2026, analyst cuts price target but maintains rating.

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...

Abbott Laboratories (NYSE:ABT) Chairman and CEO Ford Robert B. reported purchasing 18,800 shares of common stock on January 23, 2026, according to a Form 4 filing with the Securities and Exchange ...

"I think this is a little bit of an overreaction. Of course, we are all over this," Ford said. "We're focused on this, but the fundamentals of the entire rest of the company are pretty much intact, ...

ADJUSTED EARNINGS: Stripping out certain one-time items, earnings are forecast to come in at $1.50 a share. That compares with adjusted earnings of $1.34 a share a year earlier. REVENUE: Quarterly ...